New research published by University of Utah S.J. Quinney College of Law Associate Professor Jorge Contreras in the journal Science proposes that universities currently holding CRISPR patents open their licenses to broader segments of the biopharma industry — a change that could potentially lead to important discoveries for human health and medicine. The call for a new licensing model has been prompted by the emergence of CRISPR-Cas9, a revolutionary technology that can be used to edit the DNA sequence of any living organism. Contreras is available to discuss the current licensing model and how it can be corrected to benefit public welfare.
Jorge Contreras | law professor, S.J. Quinney College of Law | 801-587-5471 | Jorge.email@example.com